RELiZORB mimics the function of pancreatic lipase and delivers absorbable fats to your patients.
Learn About RELiZORB MOAIn clinical studies, use of RELiZORB was shown to normalize DHA/EPA plasma concentrations to levels consistent with a reference range based on healthy subjects as shown in the literature (please see IFU for full description of the study and references).
Starting RELiZORB
Is Simple
RELiZORB Achieves
Efficient Fat Hydrolysis
RELiZORB Support
Services
The consensus statement characterizes RELiZORB as a “physiologically superior product,” with “proven success in a real-world setting,” which “can produce measurable, clinically relevant benefits.” The statement further observed that, “despite its effectiveness and intuitive sense, RELiZORB is frequently unavailable to patients due to the vicissitudes of insurance approvals in the US.” This lack of access prompted the authors to develop an independently prepared consensus statement to highlight these patient challenges.
This information is intended for
US healthcare professionals
You are now leaving the RELiZORB
product website to view the
Alcresta Therapeutics corporate website.
